Business Context and Reporting Period
This Form 6-K filing by MDxHealth SA, dated December 19, 2022, reports on material events occurring in August 2022 and ongoing regulatory matters. The Company, a Belgian foreign private issuer, focuses on urologic diagnostics. The primary event disclosed is the acquisition of the Oncotype DX GPS (Genomic Prostate Score) prostate cancer business from Exact Sciences Corporation.
Key Financial Metrics and Transaction Details
- Acquisition Price: Up to $100 million total.
- Initial Consideration: $25 million in cash and $5 million in Company ADSs (691,171 shares at $7.23/share).
- Earn-out Potential: Up to $70 million contingent on revenue milestones for fiscal years 2023–2025 (capped at $30 million for 2023 and $40 million for 2024).
- Debt Financing: A $35 million loan secured from an affiliate of Innovatus Capital Partners to fund the acquisition and working capital.
- Debt Terms: Floating interest rate (Prime or 4.00%, whichever is higher, plus 4.25%); interest-only payments for four years; maturity on August 2, 2027.
- Conversion Rights: Lenders may convert up to 15% of principal into ADSs at $11.21 per share prior to August 2, 2025.
- Additional Capacity: Option to draw an additional $35 million ($20 million in 2024, $15 million in 2025) subject to conditions.
The filing references unaudited pro forma financial statements (Exhibit 99.2) but does not provide specific consolidated revenue, profit, or cash flow figures for MDxHealth SA within the text of this report.
Material Changes
- Business Expansion: Acquisition of the GPS test expands the Company's portfolio from biopsy decision support (Select mdx, Confirm mdx) into the cancer management pathway for early-stage prostate cancer.
- Commercial Scale: The acquisition included substantially all of Exact Sciences' urology commercial team, nearly doubling MDxHealth's sales organization to over 70 representatives, account managers, and liaisons.
- Capital Structure: Replacement of a EUR 9 million debt facility with Kreos Capital by the new $35 million Innovatus facility.
Outlook, Risks, and Contingencies
- Medicare Reimbursement Risk: While ConfirmMDx has Medicare coverage, the Select mdx test currently lacks coverage. A Technical Assessment (TA) has been submitted under the MolDX program, but final determination remains pending with no assurance of approval.
- Debt Obligations: The Company faces significant interest payments and potential dilution if the lender exercises conversion rights. Fees include a 1% facility fee and a 5% end-of-loan fee.
- Earn-out Contingency: Future cash or equity outflows depend on achieving specific revenue milestones for the acquired GPS business.
Investor Verification Checklist
- Verify the status of the Select mdx Medicare Technical Assessment and potential reimbursement timelines.
- Review the unaudited pro forma financial statements (Exhibit 99.2) to assess the impact of the acquisition on consolidated leverage and liquidity.
- Monitor the Company's ability to meet the revenue milestones required to trigger the $70 million earn-out payments.
- Assess the impact of the floating interest rate and potential share conversion on future earnings per share and debt service costs.